Matt Pauls brings more than 25 years of biopharma leadership and rare disease clinical development and commercial expertise as Atsena advances its ocular gene therapy … The post Atsena Therapeutics Appoints Matt Pauls to Board of Directors appeared first on Atsena Therapeutics .